Correction to: Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study
- PMID: 38123444
- DOI: 10.1093/bjd/ljad482
Correction to: Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study
Erratum for
-
Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.Br J Dermatol. 2023 Sep 15;189(4):400-409. doi: 10.1093/bjd/ljad156. Br J Dermatol. 2023. PMID: 37170922 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
